Phreesia (NYSE:PHR) Stock Price Expected to Rise, JMP Securities Analyst Says

Key Points

• Phreesia had its price target raised by JMP Securities from $30.00 to $34.00, indicating a potential upside of 23.20% from its current price.
• Thirteen analysts have given Phreesia a consensus rating of "Buy" with an average target price of $33.64.
• The company's recent earnings report surpassed expectations, reporting $0.01 earnings per share against an estimated loss of ($0.07).

Phreesia (NYSE:PHR - Get Free Report) had its price target increased by equities researchers at JMP Securities from $30.00 to $34.00 in a research report issued on Monday, MarketBeat reports. The firm currently has a "market outperform" rating on the stock. JMP Securities' target price would indicate a potential upside of 40.50% from the company's previous close.

Other research analysts have also recently issued research reports about the company. Raymond James Financial set a $33.00 price objective on Phreesia and gave the stock an "outperform" rating in a research report on Friday, September 5th. KeyCorp increased their price objective on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. DA Davidson assumed coverage on Phreesia in a research report on Friday, September 5th. They set a "buy" rating and a $33.00 price objective on the stock. Citigroup reissued a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. Finally, Mizuho assumed coverage on Phreesia in a report on Wednesday, August 27th. They set an "outperform" rating and a $36.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $34.08.

Phreesia Stock Performance

PHR traded down $1.28 during trading hours on Monday, reaching $24.20. The company's stock had a trading volume of 1,348,119 shares, compared to its average volume of 1,074,343. Phreesia has a 52 week low of $17.07 and a 52 week high of $32.76. The company's 50-day moving average is $28.02 and its 200-day moving average is $26.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 2.12. The firm has a market cap of $1.45 billion, a PE ratio of -57.62 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. The firm had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The company's quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, equities analysts forecast that Phreesia will post -1.1 EPS for the current year.

Insider Activity at Phreesia

In related news, insider Evan Roberts sold 3,400 shares of the firm's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $32.46, for a total value of $110,364.00. Following the sale, the insider directly owned 724,368 shares of the company's stock, valued at $23,512,985.28. This trade represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm's stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the sale, the director directly owned 22,037 shares in the company, valued at $609,763.79. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,292 shares of company stock worth $3,295,323 in the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Phreesia

Large investors have recently bought and sold shares of the business. KBC Group NV acquired a new stake in Phreesia in the first quarter valued at about $74,000. Farther Finance Advisors LLC boosted its stake in Phreesia by 9,375.0% in the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock valued at $86,000 after buying an additional 3,000 shares in the last quarter. CWM LLC boosted its stake in Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after buying an additional 3,671 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Phreesia by 53.0% in the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock valued at $137,000 after buying an additional 1,825 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Phreesia by 10,605.7% in the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after buying an additional 5,621 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.